IDEXX Laboratories (IDXX) 10-Q 31 Oct 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 24, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	IDEXX LABORATORIES INC /DE
Entity Central Index Key	874,716
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,218,713
Trading Symbol	idxx

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 169,019	$ 154,901
Marketable securities	285,085	236,949
Accounts receivable, net of reserves of $4,873 in 2017 and $4,523 in 2016	228,159	204,494
Inventories	176,749	158,034
Other current assets	83,710	91,206
Total current assets	942,722	845,584
Long-Term Assets:
Property and equipment, net	367,513	357,422
Goodwill	199,521	178,228
Intangible assets, net	45,251	46,155
Other long-term assets	114,327	103,315
Total long-term assets	726,612	685,120
TOTAL ASSETS	1,669,334	1,530,704
Current Liabilities:
Accounts payable	60,583	60,057
Accrued liabilities	220,507	236,131
Line of credit	686,250	611,000
Current portion of deferred revenue	29,203	27,380
Total current liabilities	996,543	934,568
Long-Term Liabilities:
Deferred income tax liabilities	33,205	39,287
Long-term debt	604,149	593,110
Long-term deferred revenue, net of current portion	34,245	33,015
Other long-term liabilities	49,583	38,937
Total long-term liabilities	721,182	704,349
Total liabilities	1,717,725	1,638,917
Commitments and Contingencies (Note 14)
Stockholders’ Deficit:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 104,120 shares in 2017 and 103,341 shares in 2016	10,412	10,334
Additional paid-in capital	1,060,689	1,011,895
Deferred stock units: Outstanding: 229 units in 2017 and 231 units in 2016	5,944	5,514
Retained earnings	765,288	540,401
Accumulated other comprehensive loss	(34,648)	(43,053)
Treasury stock, at cost: 16,819 shares in 2017 and 15,367 shares in 2016	(1,856,307)	(1,633,443)
Total IDEXX Laboratories, Inc. stockholders’ deficit	(48,622)	(108,352)
Noncontrolling interest	231	139
Total stockholders’ deficit	(48,391)	(108,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,669,334	$ 1,530,704

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, reserves	$ 4,873	$ 4,523
Common stock, par value	$ 0.10	$ 0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	104,120,000	103,341,000
Deferred stock units, outstanding	229,000	231,000
Treasury stock, shares	16,819,000	15,367,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Product revenue	$ 291,031	$ 266,321	$ 867,087	$ 800,273
Service revenue	200,945	181,987	595,850	532,154
Total revenue	491,976	448,308	1,462,937	1,332,427
Cost of Revenue:
Cost of product revenue	109,848	103,909	323,205	310,450
Cost of service revenue	108,126	97,669	314,824	287,167
Total cost of revenue	217,974	201,578	638,029	597,617
Gross profit	274,002	246,730	824,908	734,810
Expenses:
Sales and marketing	88,818	79,972	263,755	236,453
General and administrative	57,186	52,627	165,560	156,239
Research and development	27,585	25,672	80,373	75,704
Income from operations	100,413	88,459	315,220	266,414
Interest expense	(9,764)	(7,786)	(27,508)	(24,294)
Interest income	1,400	851	3,659	2,599
Income before provision for income taxes	92,049	81,524	291,371	244,719
Provision for income taxes	21,535	25,072	66,392	75,036
Net income	70,514	56,452	224,979	169,683
Less: Net income attributable to noncontrolling interest	3	(3)	92	7
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 70,511	$ 56,455	$ 224,887	$ 169,676
Earnings per Share:
Basic	$ 0.81	$ 0.63	$ 2.56	$ 1.89
Diluted	$ 0.79	$ 0.62	$ 2.51	$ 1.87
Weighted Average Shares Outstanding:
Basic	87,537	89,894	87,884	89,881
Diluted	89,256	91,138	89,735	90,960

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 70,514	$ 56,452	$ 224,979	$ 169,683
Other comprehensive income, net of tax:
Foreign currency translation adjustments	8,282	1,687	24,250	10,873
Unrealized loss on net investment hedge	(2,035)	(732)	(6,895)	(1,649)
Unrealized gain on investments, net of tax expense of $12 and $35 in 2017 and $19 and $134 in 2016	23	9	109	334
Unrealized loss on derivative instruments:
Unrealized loss, net of tax (benefit) of ($1,836) and ($5,035) in 2017 and ($57) and ($694) in 2016	(3,090)	(129)	(8,472)	(1,570)
Less: reclassification adjustment for loss (gains) included in net income, net of tax benefit (expense) of $333 and ($348) in 2017 and ($197) and ($313) in 2016	560	(451)	(587)	(804)
Unrealized (loss) on derivative instruments	(2,530)	(580)	(9,059)	(2,374)
Other comprehensive gain, net of tax	3,740	384	8,405	7,184
Comprehensive income	74,254	56,836	233,384	176,867
Less: comprehensive income (loss) attributable to noncontrolling interest	3	(3)	92	7
Comprehensive income attributable to IDEXX Laboratories, Inc.	$ 74,251	$ 56,839	$ 233,292	$ 176,860

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Unrealized gain on investments, tax expense (benefit)	$ 12	$ 19	$ 35	$ 134
Unrealized (loss) gain, tax (benefit) expense	(1,836)	(57)	(5,035)	(694)
Reclassification adjustment for gains included in net income, tax (benefit) expense	$ 333	$ (197)	$ (348)	$ (313)

Condensed Consolidated Stateme7

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows from Operating Activities:
Net income	$ 224,979	$ 169,683
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	61,620	57,977
Impairment charge		2,228
Provision for uncollectible accounts	1,396	842
(Provision for) benefit of deferred income taxes	(438)	6,243
Share-based compensation expense	17,762	15,021
Other	516	1,887
Tax benefit from share-based compensation arrangements (Note 2)		(10,225)
Changes in assets and liabilities:
Accounts receivable	(18,724)	(16,647)
Inventories	(22,966)	(2,503)
Other assets and liabilities	(10,734)	12,380
Accounts payable	(3,540)	(2,496)
Deferred revenue	2,279	3,798
Net cash provided by operating activities	252,150	238,188
Cash Flows from Investing Activities:
Purchases of property and equipment	(54,370)	(49,956)
Purchase of marketable securities	(269,798)	(178,829)
Proceeds from the sale and maturities of marketable securities	224,816	152,277
Acquisitions of intangible assets	(320)
Acquisitions of a business, net of cash acquired	(14,529)
Net cash used by investing activities	(114,201)	(76,508)
Cash Flows from Financing Activities:
Borrowings (repayments) on revolving credit facilities, net	75,250	(85,000)
Debt issue costs		(57)
Repurchases of common stock	(228,693)	(91,562)
Proceeds from exercises of stock options and employee stock purchase plans	31,314	28,815
Payment of acquisition-related contingent consideration		(3,633)
Shares withheld for statutory tax withholding on restricted stock (Note 2)	(7,829)	(3,732)
Tax benefit from share-based compensation arrangements (Note 2)		10,225
Net cash used by financing activities	(129,958)	(144,944)
Net effect of changes in exchange rates on cash	6,127	4,342
Net increase in cash and cash equivalents	14,118	21,078
Cash and cash equivalents at beginning of period	154,901	128,994
Cash and cash equivalents at end of period	$ 169,019	$ 150,072

Basis Of Presentation And Princ

Basis Of Presentation And Principles Of Consolidation	9 Months Ended
	Sep. 30, 2017
Basis Of Presentation And Principles Of Consolidation [Abstract]
Basis Of Presentation And Principles Of Consolidation	NOTE 1 . BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION The accompanying condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with U.S. GAAP for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to "IDEXX," the "Company," "we," "our" or "us" refer to IDEXX Laboratories, Inc. and its subsidiaries. The accompanying condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.  The accompanying condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 2016, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2017, are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, and our Annual Report on Form 10-K for the year ended December 31, 2016, (the “2016 Annual Report”) filed with the SEC.  For the nine months ended September 30, 2017, changes in stockholders’ equity included (i) changes in other comprehensive income reflected in the condensed consolidated statements of comprehensive income; (ii) changes in common stock and additional paid-in capital reflected in the condensed consolidated statements of cash flows (including share-based compensation expense, proceeds from exercise of stock options and employee stock purchase plans and repurchases of common stock); (iii) changes in noncontrolling interest; and (iv) changes in net income. 

Accounting Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Accounting Policies	NOTE 2 . ACCOUNTING POLICIES  Significant Accounting Policies  The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2017 are consistent with those discussed in Note 2 to the consolidated financial statements in our 2016 Annual Report, except as noted below.  New Accounting Pronouncements Adopted  Effective January 1, 2017, we adopted the FASB Accounting Standard Update (“ASU”) 2016-09, “Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” which simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, recognition of stock compensation award forfeitures, classification of awards as either equity or liabilities, the calculation of diluted shares outstanding and classification on the statement of cash flows.  The following table summarizes the most significant impacts of the new accounting guidance for the three and nine months ended September 30, 2017 and 2016, as applicable:     Description of Change: Impact of Change: Adoption Method:  Tax benefits related to share-based payments at settlement are recorded through the income statement instead of equity Decreases in income tax expense by approximately $3.8 million for the three months ended September 30, 2017, and approximately $22.1 million for the nine months ended September 30, 2017 Prospective (required)   Calculation of diluted shares outstanding under the treasury method will no longer assume that tax benefits related to share-based payments are used to repurchase common stock Increase in the weighted average diluted shares outstanding by approximately 450,000 shares for both the three and nine months ended September 30, 2017 Prospective (required)   An election can be made to reduce share-based compensation expense for forfeitures as they occur instead of estimating forfeitures that are expected to occur No change to share-based compensation expense, as we have elected to continue to estimate forfeitures that are expected to occur N/A   Tax benefits related to share-based payments at settlement are classified as operating cash flows instead of financing cash flows Increases in cash flow from operating activities and decreases in cash flow from financing activities by approximately $22.1 million for the nine months ended September 30, 2017 Prospective (elected)   Cash payments to tax authorities for shares withheld to meet employee tax withholding requirements on restricted stock units are classified as financing cash flow instead of operating cash flow Increases in cash flow from operating activities and decreases in cash flow from financing activities for the nine months ended September 30, 2017 and 2016 by approximately $7.8 and $3.7 million, respectively Retrospective (required) Effective July 1, 2017, we adopted ASU 2017-01, “Business Combinations (Topic 805): Clarify the Definition of a Business” which amended the definition of a business to be an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return in the form of dividends, lower costs, or other economic benefits directly to investors or other owners, members or participants. In order to be considered a business, the three elements of inputs, processes and outputs must be present. In a business acquisition, if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the integrated set of assets and activities acquired is not considered a business. We began using this guidance in analyzing acquisitions and disposals in the third quarter of 2017. This amendment may impact the allocation of purchase price in future acquisitions that are determined to be asset acquisitions as opposed to business combinations, however during the third quarter of 2017 there was no material impact on our consolidated financial statements.  New Accounting Pronouncements Not Yet Adopted  In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (the “New Revenue Standard”), which will replace most of the existing revenue recognition guidance within U.S. GAAP. The FASB has also issued several updates to ASU 2014-09. The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contract will be required. In July 2015, the FASB approved a one-year deferral of the effective date to all annual and interim periods beginning after December 15, 2017. The new guidance permits two methods of adoption: a full retrospective method to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the guidance recognized at the date of initial application. We plan to adopt ASU 2014-09, as amended, in the first quarter of 2018 on a modified-retrospective basis.  Since the issuance of ASU 2014-09, we have been preparing for the adoption of the New Revenue Standard. We have been monitoring the activity of the FASB and the Transition Resource Group as it relates to specific industry interpretive guidance and overall interpretations and clarifications. We developed a three-phase adoption plan and have completed Phase I, which included activities such as establishing a transition team and assessing significant revenue streams and representative contracts to determine potential changes to existing accounting policies . We are in Phase II of our adoption plan, during which we will further determine the impact of adoption. Phase II includes activities such as validating and concluding on changes to existing accounting policies, quantifying the effects on our consolidated financial statements, evaluating expanded disclosure requirements and addressing the impact on business processes, systems and internal controls . Phase III of our adoption plan will complete our adoption and implementation of the New Revenue Standard during the first quarter of 2018 and will include activities such as running parallel reporting for impacted areas under the New Revenue Standard and the current standard, recording the accounting adjustments that were identified in Phase II, evaluating and testing modified and newly implemented internal controls over the New Revenue Standard, and revising our financial statements disclosures.  While ASU 2014-09 will not impact the overall economics of our products and services sold under customer marketing and incentive programs, we expect the New Revenue Standard will require us to accelerate revenue recognition related to certain of our customer programs and to delay revenue recognition for certain other customer programs . We expect to accelerate revenue recognition on instruments and systems placed through programs where customers are committed to purchase future goods and services, including our up-front customer loyalty programs . This change is the result of the New Revenue Standard no longer limiting revenue recognition to the amount of customer consideration received upon placement . Conversely, we expect to defer an increased portion of revenue related to instrument placements under programs that provide rebate incentives on future purchases, including certain of our instrument marketing programs. Under the New Revenue Standard, future purchases that are optional and not subject to a customer commitment, are not considered part of the customer arrangement, resulting in the instrument absorbing a higher relative allocation of rebate incentives . We expect this change to result in lower instrument revenue upon placement and higher recurring revenues over the term of the rebate incentive program . Based on our progress to date, we believe these will be the most significant impacts related to our adoption of the New Revenue Standard, however the overall impact on our 2018 revenues is not expected to be material, as we estimate the net impact of the modified-retrospective cumulative adjustments and the change in timing of revenue recognition on 2018 activity to be relatively neutral . This assessment is based on the anticipated volume, mix and design of our customer marketing and incentive programs, which may change in response to future customer and competitive demands . Furthermore, the New Revenue Standard requires the deferral of incremental costs to obtain a customer contract over the term of the customer arrangement, such as sales commissions . Based on the current design of our sales commission plans, the impact of implementing this element of the New Revenue Standard is also not expected to be material .  In February 2017, the FASB issued ASU 2017-05, “ Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets. ” ASU 2017-05 clarifies the scope and accounting of a financial asset that meets the definition of an “in-substance nonfinancial asset” and defines the term, “in-substance nonfinancial asset.” It also adds guidance for partial sales of nonfinancial assets. The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted for interim or annual reporting periods beginning after December 15, 2016. The guidance may be applied retrospectively for all periods presented or retrospectively with a cumulative-effect adjustment at the date of adoption. The adoption of this guid ance is not expected to have an impact on our consolidated financial statements.  In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarification on accounting for modifications in share-based payment awards. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance is not expected to have an impact on our consolidated financial statements or related disclosures unless there are modifications to our share-based payment awards.  In August 2017, the FASB issued ASU 2017- 12, Derivatives and Hedging (Topic 815). The new standard amends the hedge accounting recognition and presentation requirements. The ASU also simplifies the application of the hedge accounting guidance. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the timing of adopting the new guidance as well as the impact it may have on our consolidated financial statements.  For a discussion of other accounting standards that have been issued by the FASB but are not yet effective, refer to the New Accounting Pronouncements Not Yet Adopted section in our 2016 Annual Report.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2017
Acquisitions [Abstract]
Acquisitions	 NOTE 3 . ACQUISITIONS  We believe that our acquisitions of businesses and other assets enhance our existing businesses by either expanding our geographic range and customer base or expanding our existing product lines.  On July 1, 2017, we adopted ASU 2017-01, which amended the definition of a business. During the third quarter of 2017, we acquired three reference laboratory customer lists in the United States for approximately $1.3 million and recorded these transactions as asset acquisitions. The results of operations for these reference laboratories have been included in our CAG segment since the acquisition dates.  During the second quarter of 2017 , we acquired the assets of two software companies that expand our suite of technology applications for the veterinary profession, specifically related to patient referral management and other connectivity needs between practices and other parties. The combined purchase price of $15 million consists of $12 million paid at closing and a $3 million contingent payment to be paid within 36 months if certain commercial goals are achieved . We finalized the valuation of the acquired assets in the third quarter of 2017 . The fair value estimate of the assets acquired consists of $13. 3 million of goodwill, representing synergies within our broader CAG portfolio, $1. 0 million of custo mer relationship intangibles and $0.6 million of technology intangible assets. Goodwill related to these acquisitions is expected to be ded uctible for income tax purposes . The amount of net tangible assets acquired was immaterial. Pro forma information has not been presented for these acquisitions because such information is not material to our financial statements. The results of operations have been included in our CAG segment since the acquisition date.  During the first quarter of 2017, we acquired a reference laboratory in Austria for approximately $1.3 million, with the majority of the acquisition price valued as an intangible asset. The results of operations of this reference laboratory have been included in our CAG segment since the acquisition date.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2017
Share-Based Compensation [Abstract]
Share-Based Compensation	NOTE 4 . SHARE-BASED COMPENSATION The fair value of options, restricted stock units, deferred stock units and employee stock purchase rights awarded during the three and nine months ended September 30, 2017, totaled $1.5 million and $31.0 million , respectively, as compared to $0.4 million and $26.1 million for the three and nine months ended September 30, 2016 , respectively . T he total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding at September 30, 2017, was $50.6 million, which will be recognized over a weighted average period of approximately 1.9 years. During the three and nine months ended September 30, 2017, we recognized expense of $6.1 million and $17.8 million , respectively, related to share-based compensation. We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.  The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:   For the Nine Months Ended  September 30,  2017 2016   Share price at grant $ 142.89 $ 68.94  Expected stock price volatility 26 % 25 %  Expected term, in years 5.8 5.7  Risk-free interest rate 2.0 % 1.2 %  Weighted average fair value of options granted $ 40.83 $ 17.84 

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2017
Marketable Securities [Abstract]
Marketable Securities	 Note 5 . marketable securities  The amortized cost and fair value of marketable securities were as follows ( in thousands ):    As of September 30, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 139,533 $ 129 $ (31) $ 139,631  Certificates of deposit 60,473 - - 60,473  Commercial paper 24,234 - - 24,234  Asset backed securities 22,476 11 (6) 22,481  U.S. government bonds 16,282 11 (7) 16,286  Treasury bills 10,992 1 - 10,993  Agency bonds 10,989 11 (13) 10,987  Total marketable securities $ 284,979 $ 163 $ (57) $ 285,085   As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 130,833 $ 40 $ (102) $ 130,771  Certificates of deposit 40,400 - - 40,400  Asset backed securities 27,290 25 - 27,315  Commercial paper 20,228 - - 20,228  U.S. government bonds 12,244 1 (14) 12,231  Agency bonds 4,600 4 - 4,604  Municipal bonds 1,400 - - 1,400  Total marketable securities $ 236,995 $ 70 $ (116) $ 236,949  As of September 30, 2017, unrealized losses on marketable securities that have been in a continuous loss position for more than twelve months were not material. Our portfolio of marketable securities had an average AA- credit rating as of September 30, 2017. There were no marketable securities that we consider to be other-t han-temporarily impaired as of September 30, 2017.   Remaining effective maturities of marketable securities were as follows (in thousands):     As of September 30, 2017 Amortized Cost Fair Value   Due in one year or less $ 180,221 $ 180,236  Due after one year through three years 104,758 104,849  $ 284,979 $ 285,085  Our investment strategy is to buy short-duration marketable securities with a high credit rating. Some of our marketable securities have call features that can effectively shorten the lifespan from the contractual maturity date. We use the effective maturity date to measure the duration of the marketable securities.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventories [Abstract]
Inventories	Note 6 . Inventories Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. The components of inventories were as follows (in thousands) :    September 30, December 31,  2017 2016   Raw materials $ 32,254 $ 27,561  Work-in-process 18,200 14,998  Finished goods 126,295 115,475  Inventories $ 176,749 $ 158,034 

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets, Net [Abstract]
Goodwill And Intangible Assets, Net	 NOTE 7 . G OODWILL AND INTANGIBLE ASSETS, NET We believe that our acquisitions of businesses and intangible assets enhance our existing businesses by either expanding our geographic range and customer base or expanding our existing product lines. See “Note 3. Acquisitions,” for further information regarding goodwill and intangible assets.  During the first half of 2016, management reviewed our OPTI Medical product offering, which resulted in the discontinuance of our product development activities in the human point-of-care medical diagnostics market and a decision to focus our commercial efforts to support our latest generation OPTI CCA-TS2 Blood Gas and Electrolyte Analyzer . During the first half of 2016, management identified unfavorable trends in our OPTI Medical business resulting from this change in strategy. We revised our forecasts downward, causing us to assess the realizability of the related tangible and intangible assets and determined the expected future cash flows were less than the carrying value of the OPTI Medical asset group. N on-cash intangible asset impairment s of $2.2 million were recorded within our condensed consolidated statement of operations for the six months ended June 30, 2016. 

Other Current and Long-Term Ass

Other Current and Long-Term Assets	9 Months Ended
	Sep. 30, 2017
Other Current and Long-Term Assets [Abstract]
Other Current and Long-Term Assets	NOTE 8 . Other current and long-term ASSETS  Other current assets consisted of the following (in thousands) :    September 30, December 31,  2017 2016   Prepaid expenses $ 28,233 $ 25,746  Taxes receivable 20,438 27,672  Customer acquisition costs, net 22,158 18,085  Other assets 12,881 19,703  Other current assets $ 83,710 $ 91,206  Other long-term assets consisted of the following (in thousands) :   September 30, December 31,  2017 2016   Investment in long-term product supply arrangements $ 9,060 $ 10,978  Customer acquisition costs, net 62,242 50,309  Other assets 35,111 36,321  Deferred income taxes 7,914 5,707  Other long-term assets $ 114,327 $ 103,315 

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2017
Accrued Liabilities [Abstract]
Accrued Liabilities	 Note 9 . Accrued liabilities Accrued liabilities consisted of the following (in thousands) :    September 30, December 31,  2017 2016   Accrued expenses $ 60,774 $ 71,984  Accrued employee compensation and related expenses 79,687 91,113  Accrued taxes 24,859 23,973  Accrued customer programs 55,187 49,061  Accrued liabilities $ 220,507 $ 236,131 

Repurchases Of Common Stock

Repurchases Of Common Stock	9 Months Ended
	Sep. 30, 2017
Repurchases Of Common Stock [Abstract]
Repurchases Of Common Stock	 Note 10 . Repurchases of common STOCK   We primarily acquire shares by repurchases in the open market. However, we also acquire shares that are surrendered by employees in payment for the minimum required statutory withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders.  We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury stock issued during the three and nine months ended September 30, 2017 and 2016 was not material.  The following is a summary of our open market common stock repurchases, reported on a trade date basis, and shares acquired through employee surrender for the three and nine months ended September 30, 2017 and 2016 (in thousands, except per share amounts) :    For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016   Shares repurchased in the open market 312 142 1,398 1,119  Shares acquired through employee surrender for statutory tax withholding 2 2 55 56  Total shares repurchased 314 144 1,453 1,175   Cost of shares repurchased in the open market $ 50,413 $ 15,260 $ 215,320 $ 88,235  Cost of shares for employee surrenders 370 218 7,829 3,950  Total cost of shares $ 50,783 $ 15,478 $ 223,149 $ 92,185   Average cost per share - open market repurchase $ 161.57 $ 107.38 $ 153.99 $ 78.84  Average cost per share - employee surrenders $ 155.14 $ 112.91 $ 142.15 $ 70.33  Average cost per share - total $ 161.52 $ 107.46 $ 153.54 $ 78.43 

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Taxes [Abstract]
Income Taxes	 Note 11 . Income Taxes Our effective income tax rate was 23.4 percent for the three months ended September 30, 2017, as compared to 30.8 percent for the three months ended September 30, 2016, and 22.8 percent for the nine months ended September 30, 2017, as compared to 30.7 percent for the nine months ended September 30, 2016.  The decrease in our effective tax rate for the three months ended September 30, 2017, as compared to the same period in the prior year, was primarily related to the adoption of ASU 2016-09 related to share-based compensation, which reduced our effective tax rate by approximately 4 percent, and the expected utilization of foreign tax credits, which reduced our effective tax rate by approximately 3 percent.  The decrease in our effective tax rate for the nine months ended September 30, 2017, as compared to the same period in the prior year, was primarily related to the adoption of ASU 2016-09 related to share-based compensation, which reduced our effective tax rate by approximately 8 percent, and the expected utilization of foreign tax credits, which reduced our effective tax rate by approximately 1 percent. See “Note 2. Accounting Policies”, for more information regarding the adoption of ASU 2016-09.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2017
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	Note 12 . ACCUMULATED OTHER Comprehensive Income The changes in AOCI, net of tax, for the nine months ended September 30, 2017 consisted of the following (in thousands) :   For the Nine Months Ended September 30, 2017 Unrealized Gain on Investments, Net of Tax Unrealized Gain (Loss) on Derivative Instruments, Net of Tax Unrealized Gain (Loss) on Net Investment Hedge, Net of Tax Cumulative Translation Adjustment Total   Balance as of December 31, 2016 $ 20 $ 4,916 $ 4,036 $ (52,025) $ (43,053)  Other comprehensive income (loss) before reclassifications 109 (8,472) (6,895) 24,250 8,992  Gains reclassified from accumulated other comprehensive income - (587) - - (587)  Balance as of September 30, 2017 $ 129 $ (4,143) $ (2,859) $ (27,775) $ (34,648)          The following is a summary of reclassifications out of AOCI for the three and nine months ended September 30, 2017 and 2016 (in thousands) :     Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Three Months Ended September 30,  2017 2016  (Losses) gains on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ (893) $ 648  Total (losses) gains before tax (893) 648  Tax (benefits) expense (333) 197  (Losses) gains, net of tax $ (560) $ 451   Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Nine Months Ended September 30,  2017 2016  Gains (losses) on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ 935 $ 1,538  Interest rate swaps Interest expense - (421)  Total gains before tax 935 1,117  Tax expense 348 313  Gains, net of tax $ 587 $ 804 

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share	Note 13 . Earnings per Share Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and, prior to the adoption of new accounting guidance related to share-based compensation on January 1, 2017, the tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. For further discussion regarding the impact of the new accounting guidance related to share-based compensation, see “Note 2. Accounting Policies.” Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 4 to the consolidated financial statements in our 2016 Annual Report for additional information regarding deferred stock units .  The following is a reconciliation of weighted average shares outstanding for basic and diluted earnin gs per share for the three and nine months ended September 30, 2017 and 2016 (in thousands) :   For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016   Shares outstanding for basic earnings per share 87,537 89,894 87,884 89,881   Shares outstanding for diluted earnings per share:  Shares outstanding for basic earnings per share 87,537 89,894 87,884 89,881  Dilutive effect of share-based payment awards 1,719 1,244 1,851 1,079  89,256 91,138 89,735 90,960    Certain options to acquire shares and restricted stock units have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive options and restricted stock units for the three and nine months ended September 30, 2017 and 2016 (in thousands ):   For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016   Weighted average number of shares underlying anti-dilutive options 377 - 310 520   Weighted average number of shares underlying anti-dilutive restricted stock units - - - - 

Commitments, Contingencies And

Commitments, Contingencies And Guarantees	9 Months Ended
	Sep. 30, 2017
Commitments, Contingencies And Guarantees [Abstract]
Commitments, Contingencies And Guarantees	Note 14 . Commitments, Contingencies and Guarantees Significant commitments, c ontingencies and guarantees at September 30, 2017 , are consistent with those discussed in Note 14 to the consolidated financial statements in our 2016 Annual Report.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segment Reporting	Note 15 . Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry he alth and to ensure the quality and safety of milk and improve dairy efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments.  Certain costs are not allocated to our operating segments and are instead reported under the caption “Unallocated Amounts . ” These costs include costs that do not align with one of our existing operating segments or are cost prohibitive to allocate, which primarily consist of our R&D function, regional or country expenses, certain foreign currency revaluation gains and losses on monetary balances in currencies other than our subsidiaries’ functional currency and unusual items. Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation are charged to our business segments at pre-determined budgeted amounts or rates. Differences from these pre-determined budgeted amounts or rates are captured within Unallocated Amounts.  The following is a summary of segment performance for the three and nine months ended September 30, 2017 and 2016 (in thousands) :        For the Three Months Ended September 30,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2017  Revenue $ 426,686 $ 31,030 $ 28,396 $ 5,864 $ - $ 491,976   Income (loss) from operations $ 89,271 $ 14,505 $ 902 $ 2,114 $ (6,379) $ 100,413  Interest expense, net (8,364)  Income before provision for income taxes 92,049  Provision for income taxes 21,535  Net income 70,514  Less: Net income attributable to noncontrolling interest 3  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 70,511   2016  Revenue $ 385,288 $ 27,862 $ 29,799 $ 5,359 $ - $ 448,308   Income (loss) from operations $ 77,493 $ 12,442 $ 3,026 $ 1,008 $ (5,510) $ 88,459  Interest expense, net (6,935)  Income before provision for income taxes 81,524  Provision for income taxes 25,072  Net income 56,452  Less: Net income attributable to noncontrolling interest (3)  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 56,455      For the Nine Months Ended September 30,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2017  Revenue $ 1,269,861 $ 85,531 $ 91,266 $ 16,279 $ - $ 1,462,937   Income (loss) from operations $ 277,857 $ 38,421 $ 9,880 $ 3,275 $ (14,213) $ 315,220  Interest expense, net (23,849)  Income before provision for income taxes 291,371  Provision for income taxes 66,392  Net income 224,979  Less: Net income attributable to noncontrolling interest 92  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 224,887   2016  Revenue $ 1,143,150 $ 79,243 $ 93,511 $ 16,523 $ - $ 1,332,427   Income (loss) from operations $ 229,858 $ 34,864 $ 12,665 $ (749) $ (10,224) $ 266,414  Interest expense, net (21,695)  Income before provision for income taxes 244,719  Provision for income taxes 75,036  Net income 169,683  Less: Net income attributable to noncontrolling interest 7  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 169,676    The following is a summary of revenue by product and serv ice category for the three and nine months ended September 30, 2017 and 2016 ( in thousands ):   For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016  CAG segment revenue:  CAG Diagnostics recurring revenue: $ 364,937 $ 324,603 $ 1,091,936 $ 969,097  IDEXX VetLab consumables 129,434 113,964 385,081 336,493  Rapid assay products 50,924 48,720 159,085 147,583  Reference laboratory diagnostic and consulting services 167,851 146,672 498,218 440,514  CAG Diagnostics service and accessories 16,728 15,247 49,552 44,507  CAG Diagnostics capital - instruments 29,119 31,255 83,018 86,063  Veterinary software, services and diagnostic imaging systems 32,630 29,430 94,907 87,990  CAG segment revenue 426,686 385,288 1,269,861 1,143,150   Water segment revenue 31,030 27,862 85,531 79,243  LPD segment revenue 28,396 29,799 91,266 93,511  Other segment revenue 5,864 5,359 16,279 16,523  Total revenue $ 491,976 $ 448,308 $ 1,462,937 $ 1,332,427   During the fourth quarter of 2016, we modified our management reporting and reclassified the location of SNAP P ro service plans previously located in CAG Diagnostics capital - instruments to CAG Diagnostics service and accessories. The amount of revenue reclassified was $0.4 million during the three months ended September 30, 2016 and $1.1 million for the nine months ended September 30, 2016.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 16 . FAIR VALUE MEASUREMENTS U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value .  We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three and nine months ended September 30, 2017.  Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate the prices provided by our third-party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances.   Our foreign currency exchange contracts are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.  The amounts outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit”) and senior notes (“long-term debt”) are measured at carrying value in our condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using Level 2 inputs. The estimated fair value of our Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt were $631.0 million and $ 604.7 million, respectively, as of September 30, 2017, and $609.5 million and $593.7 million, respectively, as of December 31, 2016.  The following tables set forth our assets and liabilities that were measured at fair value on a recurring basis at September 30, 2017 , and at December 31, 2016 , by level within the fair value hierarchy (in thousands) :    Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of September 30, 2017 (Level 1) (Level 2) (Level 3) September 30, 2017   Assets  Money market funds (1) $ 20,924 $ - $ - $ 20,924  Commercial paper (1) - 3,089 - 3,089  Corporate bonds (1) - 2,500 - 2,500  Certificates of deposit (1) - 750 - 750   Marketable Securities  Corporate bonds - 139,631 - 139,631  Certificates of deposit - 60,473 - 60,473  Commercial paper - 24,234 - 24,234  Asset backed securities - 22,481 - 22,481  U.S. government bonds - 16,286 - 16,286  Treasury bills 10,993 10,993  Agency bonds - 10,987 - 10,987  Total marketable securities $ - $ 285,085 $ - $ 285,085   Equity mutual funds (2) $ 2,119 $ - $ - $ 2,119  Foreign currency exchange contracts (3) $ - $ 971 $ - $ 971  Liabilities  Foreign currency exchange contracts (3) $ - $ 7,004 $ - $ 7,004  Deferred compensation (4) $ 2,119 $ - $ - $ 2,119     Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of December 31, 2016 (Level 1) (Level 2) (Level 3) December 31, 2016   Assets  Money market funds (1) $ 34,208 $ - $ - $ 34,208  Certificates of deposit (1) - 1,500 - 1,500  Commercial paper (1) - 898 - 898   Marketable Securities  Corporate bonds - 130,771 - 130,771  Certificates of deposit - 40,400 - 40,400  Asset backed securities - 27,315 - 27,315  Commercial paper - 20,228 - 20,228  U.S. government bonds - 12,231 - 12,231  Agency bonds - 4,604 - 4,604  Municipal bonds - 1,400 - 1,400  Total marketable securities $ - $ 236,949 $ - $ 236,949   Equity mutual funds (2) $ 2,182 $ - $ - $ 2,182  Foreign currency exchange contracts (3) $ - $ 8,926 $ - $ 8,926  Liabilities  Foreign currency exchange contracts (3) $ - $ 1,081 $ - $ 1,081  Deferred compensation (4) $ 2,182 $ - $ - $ 2,182 _____________ (1) Money market funds, certificates of deposit and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of September 30, 2017, and December 31, 2016, consisted of demand deposits . Commercial paper and certificates of deposit with an original maturity of over ninety days are included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets; other long-term assets; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date . (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above .  The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Hedging Instruments

Hedging Instruments	9 Months Ended
	Sep. 30, 2017
Hedging Instruments [Abstract]
Hedging Instruments	Note 17 . HEDGING Instruments Disclosure within this note is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively “hedging instruments”), how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows . We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions .  We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings . See “Note 12. Accumulated Other Comprehensive Income” for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016.  We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment . We did not de-designate any instruments from hedge accounting treatment during the three and nine months ended September 30, 2017 or 2016. Gains or losses related to hedge ineffectiveness recognized in earnings during the three and nine months ended September 30, 2017 and 2016 were not material . At September 30, 2017, the estimated amount of net losses, net of income tax benefit, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $3.2 million if exchange rates do not fluctuate from the levels at September 30, 2017. We hedge approximately 85 percent of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, Australian dollar and Swiss franc. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $184.5 million and $175.9 million at September 30, 2017 and December 31, 2016, respectively. We previously entered into forward fixed interest rate swap agreements to manage the economic effect of variable interest obligations on amounts borrowed under the terms of our Credit Facility. Beginning on March 30, 2012, the variable interest rate associated with $40 million of borrowings outstanding under the Credit Facility was effectively fixed at 1.36 percent plus the range of applicable interest rate fixed credit spreads (“Credit Spread”) through June 30, 2016. Beginning on March 28, 2013, the variable interest rate associated with an additional $40 million of borrowings outstanding under the Credit Facility was effectively fixed at 1.64 percent plus the Credit Spread through June 30, 2016. From July 1, 2016, to September 30, 2017, we had no outstanding interest rate swap agreements.  Net Investment Hedge  In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million in euro-denominated 1.785 percent Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded losses of $2.0 million and $ 6 . 9 million , net of income tax, within AOCI as a result of this net investment hedge for the three and nine months ended September 30, 2017, respectively. The related cumulative unrealized loss recorded at September 30, 2017 will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations or a portion of the hedge no longer qualifies for hedge accounting treatment. See Note 11 to the consolidated financial statements included in our 2016 Annual Report for further information regarding the issuance of these euro-denominated notes.  Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets  The fair values of hedging instruments and their respective classification on the condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following (in thousands) :   Hedging Assets  September 30, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Other current assets $ 855 $ 8,926  Foreign currency exchange contracts Other long-term assets 116 -  Total derivative instruments presented as cash flow hedges on the balance sheet 971 8,926  Gross amounts subject to master netting arrangements not offset on the balance sheet 971 679  Net amount $ - $ 8,247     Hedging Liabilities  September 30, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Accrued liabilities $ 5,537 $ 1,081  Foreign currency exchange contracts Other long-term liabilities 1,467 -  Total derivative instruments presented as cash flow hedges on the balance sheet 7,004 1,081  Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 104,656 93,664  Total hedging instruments presented on the balance sheet 111,660 94,745  Gross amounts subject to master netting arrangements not offset on the balance sheet 971 679  Net amount $ 110,689 $ 94,066  The effect of derivative instruments designated as cash flow hedges on the condensed consolidated balance sheets consisted of the following (in thousands) :    Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion)  For the Three Months Ended For the Nine Months Ended  September 30, September 30,  Derivative instruments 2017 2016 2017 2016   Cash flow hedging derivatives:  Foreign currency exchange contracts, net of tax $ (2,530) $ (580) $ (9,059) $ (2,616)  Interest rate swaps, net of tax - - - 242  Total cash flow hedges $ (2,530) $ (580) $ (9,059) $ (2,374) 

Accounting Policies (Policy)

Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements Adopted	New Accounting Pronouncements Adopted  Effective January 1, 2017, we adopted the FASB Accounting Standard Update (“ASU”) 2016-09, “Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” which simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, recognition of stock compensation award forfeitures, classification of awards as either equity or liabilities, the calculation of diluted shares outstanding and classification on the statement of cash flows.  The following table summarizes the most significant impacts of the new accounting guidance for the three and nine months ended September 30, 2017 and 2016, as applicable:     Description of Change: Impact of Change: Adoption Method:  Tax benefits related to share-based payments at settlement are recorded through the income statement instead of equity Decreases in income tax expense by approximately $3.8 million for the three months ended September 30, 2017, and approximately $22.1 million for the nine months ended September 30, 2017 Prospective (required)   Calculation of diluted shares outstanding under the treasury method will no longer assume that tax benefits related to share-based payments are used to repurchase common stock Increase in the weighted average diluted shares outstanding by approximately 450,000 shares for both the three and nine months ended September 30, 2017 Prospective (required)   An election can be made to reduce share-based compensation expense for forfeitures as they occur instead of estimating forfeitures that are expected to occur No change to share-based compensation expense, as we have elected to continue to estimate forfeitures that are expected to occur N/A   Tax benefits related to share-based payments at settlement are classified as operating cash flows instead of financing cash flows Increases in cash flow from operating activities and decreases in cash flow from financing activities by approximately $22.1 million for the nine months ended September 30, 2017 Prospective (elected)   Cash payments to tax authorities for shares withheld to meet employee tax withholding requirements on restricted stock units are classified as financing cash flow instead of operating cash flow Increases in cash flow from operating activities and decreases in cash flow from financing activities for the nine months ended September 30, 2017 and 2016 by approximately $7.8 and $3.7 million, respectively Retrospective (required) Effective July 1, 2017, we adopted ASU 2017-01, “Business Combinations (Topic 805): Clarify the Definition of a Business” which amended the definition of a business to be an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return in the form of dividends, lower costs, or other economic benefits directly to investors or other owners, members or participants. In order to be considered a business, the three elements of inputs, processes and outputs must be present. In a business acquisition, if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, the integrated set of assets and activities acquired is not considered a business. We began using this guidance in analyzing acquisitions and disposals in the third quarter of 2017. This amendment may impact the allocation of purchase price in future acquisitions that are determined to be asset acquisitions as opposed to business combinations, however during the third quarter of 2017 there was no material impact on our consolidated financial statements.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted  In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (the “New Revenue Standard”), which will replace most of the existing revenue recognition guidance within U.S. GAAP. The FASB has also issued several updates to ASU 2014-09. The core principle of ASU 2014-09 is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contract will be required. In July 2015, the FASB approved a one-year deferral of the effective date to all annual and interim periods beginning after December 15, 2017. The new guidance permits two methods of adoption: a full retrospective method to each prior reporting period presented or a modified retrospective approach with the cumulative effect of initially applying the guidance recognized at the date of initial application. We plan to adopt ASU 2014-09, as amended, in the first quarter of 2018 on a modified-retrospective basis.  Since the issuance of ASU 2014-09, we have been preparing for the adoption of the New Revenue Standard. We have been monitoring the activity of the FASB and the Transition Resource Group as it relates to specific industry interpretive guidance and overall interpretations and clarifications. We developed a three-phase adoption plan and have completed Phase I, which included activities such as establishing a transition team and assessing significant revenue streams and representative contracts to determine potential changes to existing accounting policies . We are in Phase II of our adoption plan, during which we will further determine the impact of adoption. Phase II includes activities such as validating and concluding on changes to existing accounting policies, quantifying the effects on our consolidated financial statements, evaluating expanded disclosure requirements and addressing the impact on business processes, systems and internal controls . Phase III of our adoption plan will complete our adoption and implementation of the New Revenue Standard during the first quarter of 2018 and will include activities such as running parallel reporting for impacted areas under the New Revenue Standard and the current standard, recording the accounting adjustments that were identified in Phase II, evaluating and testing modified and newly implemented internal controls over the New Revenue Standard, and revising our financial statements disclosures.  While ASU 2014-09 will not impact the overall economics of our products and services sold under customer marketing and incentive programs, we expect the New Revenue Standard will require us to accelerate revenue recognition related to certain of our customer programs and to delay revenue recognition for certain other customer programs . We expect to accelerate revenue recognition on instruments and systems placed through programs where customers are committed to purchase future goods and services, including our up-front customer loyalty programs . This change is the result of the New Revenue Standard no longer limiting revenue recognition to the amount of customer consideration received upon placement . Conversely, we expect to defer an increased portion of revenue related to instrument placements under programs that provide rebate incentives on future purchases, including certain of our instrument marketing programs. Under the New Revenue Standard, future purchases that are optional and not subject to a customer commitment, are not considered part of the customer arrangement, resulting in the instrument absorbing a higher relative allocation of rebate incentives . We expect this change to result in lower instrument revenue upon placement and higher recurring revenues over the term of the rebate incentive program . Based on our progress to date, we believe these will be the most significant impacts related to our adoption of the New Revenue Standard, however the overall impact on our 2018 revenues is not expected to be material, as we estimate the net impact of the modified-retrospective cumulative adjustments and the change in timing of revenue recognition on 2018 activity to be relatively neutral . This assessment is based on the anticipated volume, mix and design of our customer marketing and incentive programs, which may change in response to future customer and competitive demands . Furthermore, the New Revenue Standard requires the deferral of incremental costs to obtain a customer contract over the term of the customer arrangement, such as sales commissions . Based on the current design of our sales commission plans, the impact of implementing this element of the New Revenue Standard is also not expected to be material .  In February 2017, the FASB issued ASU 2017-05, “ Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets. ” ASU 2017-05 clarifies the scope and accounting of a financial asset that meets the definition of an “in-substance nonfinancial asset” and defines the term, “in-substance nonfinancial asset.” It also adds guidance for partial sales of nonfinancial assets. The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted for interim or annual reporting periods beginning after December 15, 2016. The guidance may be applied retrospectively for all periods presented or retrospectively with a cumulative-effect adjustment at the date of adoption. The adoption of this guid ance is not expected to have an impact on our consolidated financial statements.  In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarification on accounting for modifications in share-based payment awards. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance is not expected to have an impact on our consolidated financial statements or related disclosures unless there are modifications to our share-based payment awards.  In August 2017, the FASB issued ASU 2017- 12, Derivatives and Hedging (Topic 815). The new standard amends the hedge accounting recognition and presentation requirements. The ASU also simplifies the application of the hedge accounting guidance. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the timing of adopting the new guidance as well as the impact it may have on our consolidated financial statements.

Share-Based Compensation (Polic

Share-Based Compensation (Policy)	9 Months Ended
	Sep. 30, 2017
Share-Based Compensation [Abstract]
Share-Based Compensation Policy	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.

Inventories (Policy)

Inventories (Policy)	9 Months Ended
	Sep. 30, 2017
Inventories [Abstract]
Inventories Policy	Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges.

Earnings Per Share (Policy)

Earnings Per Share (Policy)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share Policy	Basic earnings per share is computed by dividing net income attributable to our stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and, prior to the adoption of new accounting guidance related to share-based compensation on January 1, 2017, the tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. For further discussion regarding the impact of the new accounting guidance related to share-based compensation, see “Note 2. Accounting Policies.” Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent.

Fair Value Measurements (Policy

Fair Value Measurements (Policy)	9 Months Ended
	Sep. 30, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements Policy	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value .  We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three and nine months ended September 30, 2017.  Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate the prices provided by our third-party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances.   Our foreign currency exchange contracts are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk.  The amounts outstanding under our unsecured revolving credit facility (“Credit Facility” or “line of credit”) and senior notes (“long-term debt”) are measured at carrying value in our condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and long-term debt are valued using Level 2 inputs.

Hedging Instuments (Policy)

Hedging Instuments (Policy)	9 Months Ended
	Sep. 30, 2017
Hedging Instruments [Abstract]
Derivatives Policy	We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures, including net investments in certain foreign subsidiaries. We may also enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in the euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign currency exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions .  We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. Instruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cash flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earnings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings . See “Note 12. Accumulated Other Comprehensive Income” for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016.  We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment

Accounting Policies (Tables)

Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary Of The Most Significant Impacts Of The New Accounting Guidance	  Description of Change: Impact of Change: Adoption Method:  Tax benefits related to share-based payments at settlement are recorded through the income statement instead of equity Decreases in income tax expense by approximately $3.8 million for the three months ended September 30, 2017, and approximately $22.1 million for the nine months ended September 30, 2017 Prospective (required)   Calculation of diluted shares outstanding under the treasury method will no longer assume that tax benefits related to share-based payments are used to repurchase common stock Increase in the weighted average diluted shares outstanding by approximately 450,000 shares for both the three and nine months ended September 30, 2017 Prospective (required)   An election can be made to reduce share-based compensation expense for forfeitures as they occur instead of estimating forfeitures that are expected to occur No change to share-based compensation expense, as we have elected to continue to estimate forfeitures that are expected to occur N/A   Tax benefits related to share-based payments at settlement are classified as operating cash flows instead of financing cash flows Increases in cash flow from operating activities and decreases in cash flow from financing activities by approximately $22.1 million for the nine months ended September 30, 2017 Prospective (elected)   Cash payments to tax authorities for shares withheld to meet employee tax withholding requirements on restricted stock units are classified as financing cash flow instead of operating cash flow Increases in cash flow from operating activities and decreases in cash flow from financing activities for the nine months ended September 30, 2017 and 2016 by approximately $7.8 and $3.7 million, respectively Retrospective (required) 

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Share-Based Compensation [Abstract]
Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards	  For the Nine Months Ended  September 30,  2017 2016   Share price at grant $ 142.89 $ 68.94  Expected stock price volatility 26 % 25 %  Expected term, in years 5.8 5.7  Risk-free interest rate 2.0 % 1.2 %  Weighted average fair value of options granted $ 40.83 $ 17.84 

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2017
Marketable Securities [Abstract]
Amortized Cost And Fair Value Of Marketable Securities	  As of September 30, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 139,533 $ 129 $ (31) $ 139,631  Certificates of deposit 60,473 - - 60,473  Commercial paper 24,234 - - 24,234  Asset backed securities 22,476 11 (6) 22,481  U.S. government bonds 16,282 11 (7) 16,286  Treasury bills 10,992 1 - 10,993  Agency bonds 10,989 11 (13) 10,987  Total marketable securities $ 284,979 $ 163 $ (57) $ 285,085   As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 130,833 $ 40 $ (102) $ 130,771  Certificates of deposit 40,400 - - 40,400  Asset backed securities 27,290 25 - 27,315  Commercial paper 20,228 - - 20,228  U.S. government bonds 12,244 1 (14) 12,231  Agency bonds 4,600 4 - 4,604  Municipal bonds 1,400 - - 1,400  Total marketable securities $ 236,995 $ 70 $ (116) $ 236,949 
Contractual Maturities Of Marketable Securities	  As of September 30, 2017 Amortized Cost Fair Value   Due in one year or less $ 180,221 $ 180,236  Due after one year through three years 104,758 104,849  $ 284,979 $ 285,085 

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventories [Abstract]
Schedule Of Components Of Inventories	  September 30, December 31,  2017 2016   Raw materials $ 32,254 $ 27,561  Work-in-process 18,200 14,998  Finished goods 126,295 115,475  Inventories $ 176,749 $ 158,034 

Other Current and Long-Term A35

Other Current and Long-Term Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Other Current and Long-Term Assets [Abstract]
Schedule Of Other Current Assets	  September 30, December 31,  2017 2016   Prepaid expenses $ 28,233 $ 25,746  Taxes receivable 20,438 27,672  Customer acquisition costs, net 22,158 18,085  Other assets 12,881 19,703  Other current assets $ 83,710 $ 91,206 
Schedule Of Other Long-term Assets	  September 30, December 31,  2017 2016   Investment in long-term product supply arrangements $ 9,060 $ 10,978  Customer acquisition costs, net 62,242 50,309  Other assets 35,111 36,321  Deferred income taxes 7,914 5,707  Other long-term assets $ 114,327 $ 103,315 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  September 30, December 31,  2017 2016   Accrued expenses $ 60,774 $ 71,984  Accrued employee compensation and related expenses 79,687 91,113  Accrued taxes 24,859 23,973  Accrued customer programs 55,187 49,061  Accrued liabilities $ 220,507 $ 236,131 

Repurchases Of Common Stock (Ta

Repurchases Of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2017
Repurchases Of Common Stock [Abstract]
Schedule Of Common Stock Repurchases	  For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016   Shares repurchased in the open market 312 142 1,398 1,119  Shares acquired through employee surrender for statutory tax withholding 2 2 55 56  Total shares repurchased 314 144 1,453 1,175   Cost of shares repurchased in the open market $ 50,413 $ 15,260 $ 215,320 $ 88,235  Cost of shares for employee surrenders 370 218 7,829 3,950  Total cost of shares $ 50,783 $ 15,478 $ 223,149 $ 92,185   Average cost per share - open market repurchase $ 161.57 $ 107.38 $ 153.99 $ 78.84  Average cost per share - employee surrenders $ 155.14 $ 112.91 $ 142.15 $ 70.33  Average cost per share - total $ 161.52 $ 107.46 $ 153.54 $ 78.43 

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2017
Accumulated Other Comprehensive Income [Abstract]
Schedule Of Accumulated Other Comprehensive Income	  For the Nine Months Ended September 30, 2017 Unrealized Gain on Investments, Net of Tax Unrealized Gain (Loss) on Derivative Instruments, Net of Tax Unrealized Gain (Loss) on Net Investment Hedge, Net of Tax Cumulative Translation Adjustment Total   Balance as of December 31, 2016 $ 20 $ 4,916 $ 4,036 $ (52,025) $ (43,053)  Other comprehensive income (loss) before reclassifications 109 (8,472) (6,895) 24,250 8,992  Gains reclassified from accumulated other comprehensive income - (587) - - (587)  Balance as of September 30, 2017 $ 129 $ (4,143) $ (2,859) $ (27,775) $ (34,648) 
Summary Of Reclassifications Out Of Accumulated Other Comprehensive Income	  Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Three Months Ended September 30,  2017 2016  (Losses) gains on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ (893) $ 648  Total (losses) gains before tax (893) 648  Tax (benefits) expense (333) 197  (Losses) gains, net of tax $ (560) $ 451   Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Nine Months Ended September 30,  2017 2016  Gains (losses) on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ 935 $ 1,538  Interest rate swaps Interest expense - (421)  Total gains before tax 935 1,117  Tax expense 348 313  Gains, net of tax $ 587 $ 804 

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share	  For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016   Shares outstanding for basic earnings per share 87,537 89,894 87,884 89,881   Shares outstanding for diluted earnings per share:  Shares outstanding for basic earnings per share 87,537 89,894 87,884 89,881  Dilutive effect of share-based payment awards 1,719 1,244 1,851 1,079  89,256 91,138 89,735 90,960 
Schedule Of Number Of Anti-Dilutive Stock Options	  For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016   Weighted average number of shares underlying anti-dilutive options 377 - 310 520   Weighted average number of shares underlying anti-dilutive restricted stock units - - - - 

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Summary Of Segment Performance	  For the Three Months Ended September 30,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2017  Revenue $ 426,686 $ 31,030 $ 28,396 $ 5,864 $ - $ 491,976   Income (loss) from operations $ 89,271 $ 14,505 $ 902 $ 2,114 $ (6,379) $ 100,413  Interest expense, net (8,364)  Income before provision for income taxes 92,049  Provision for income taxes 21,535  Net income 70,514  Less: Net income attributable to noncontrolling interest 3  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 70,511   2016  Revenue $ 385,288 $ 27,862 $ 29,799 $ 5,359 $ - $ 448,308   Income (loss) from operations $ 77,493 $ 12,442 $ 3,026 $ 1,008 $ (5,510) $ 88,459  Interest expense, net (6,935)  Income before provision for income taxes 81,524  Provision for income taxes 25,072  Net income 56,452  Less: Net income attributable to noncontrolling interest (3)  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 56,455      For the Nine Months Ended September 30,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2017  Revenue $ 1,269,861 $ 85,531 $ 91,266 $ 16,279 $ - $ 1,462,937   Income (loss) from operations $ 277,857 $ 38,421 $ 9,880 $ 3,275 $ (14,213) $ 315,220  Interest expense, net (23,849)  Income before provision for income taxes 291,371  Provision for income taxes 66,392  Net income 224,979  Less: Net income attributable to noncontrolling interest 92  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 224,887   2016  Revenue $ 1,143,150 $ 79,243 $ 93,511 $ 16,523 $ - $ 1,332,427   Income (loss) from operations $ 229,858 $ 34,864 $ 12,665 $ (749) $ (10,224) $ 266,414  Interest expense, net (21,695)  Income before provision for income taxes 244,719  Provision for income taxes 75,036  Net income 169,683  Less: Net income attributable to noncontrolling interest 7  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 169,676 
Summary Of Revenue By Product And Service Category	  For the Three Months Ended For the Nine Months Ended  September 30, September 30,  2017 2016 2017 2016  CAG segment revenue:  CAG Diagnostics recurring revenue: $ 364,937 $ 324,603 $ 1,091,936 $ 969,097  IDEXX VetLab consumables 129,434 113,964 385,081 336,493  Rapid assay products 50,924 48,720 159,085 147,583  Reference laboratory diagnostic and consulting services 167,851 146,672 498,218 440,514  CAG Diagnostics service and accessories 16,728 15,247 49,552 44,507  CAG Diagnostics capital - instruments 29,119 31,255 83,018 86,063  Veterinary software, services and diagnostic imaging systems 32,630 29,430 94,907 87,990  CAG segment revenue 426,686 385,288 1,269,861 1,143,150   Water segment revenue 31,030 27,862 85,531 79,243  LPD segment revenue 28,396 29,799 91,266 93,511  Other segment revenue 5,864 5,359 16,279 16,523  Total revenue $ 491,976 $ 448,308 $ 1,462,937 $ 1,332,427 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Measurements [Abstract]
Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis	  Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of September 30, 2017 (Level 1) (Level 2) (Level 3) September 30, 2017   Assets  Money market funds (1) $ 20,924 $ - $ - $ 20,924  Commercial paper (1) - 3,089 - 3,089  Corporate bonds (1) - 2,500 - 2,500  Certificates of deposit (1) - 750 - 750   Marketable Securities  Corporate bonds - 139,631 - 139,631  Certificates of deposit - 60,473 - 60,473  Commercial paper - 24,234 - 24,234  Asset backed securities - 22,481 - 22,481  U.S. government bonds - 16,286 - 16,286  Treasury bills 10,993 10,993  Agency bonds - 10,987 - 10,987  Total marketable securities $ - $ 285,085 $ - $ 285,085   Equity mutual funds (2) $ 2,119 $ - $ - $ 2,119  Foreign currency exchange contracts (3) $ - $ 971 $ - $ 971  Liabilities  Foreign currency exchange contracts (3) $ - $ 7,004 $ - $ 7,004  Deferred compensation (4) $ 2,119 $ - $ - $ 2,119     Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of December 31, 2016 (Level 1) (Level 2) (Level 3) December 31, 2016   Assets  Money market funds (1) $ 34,208 $ - $ - $ 34,208  Certificates of deposit (1) - 1,500 - 1,500  Commercial paper (1) - 898 - 898   Marketable Securities  Corporate bonds - 130,771 - 130,771  Certificates of deposit - 40,400 - 40,400  Asset backed securities - 27,315 - 27,315  Commercial paper - 20,228 - 20,228  U.S. government bonds - 12,231 - 12,231  Agency bonds - 4,604 - 4,604  Municipal bonds - 1,400 - 1,400  Total marketable securities $ - $ 236,949 $ - $ 236,949   Equity mutual funds (2) $ 2,182 $ - $ - $ 2,182  Foreign currency exchange contracts (3) $ - $ 8,926 $ - $ 8,926  Liabilities  Foreign currency exchange contracts (3) $ - $ 1,081 $ - $ 1,081  Deferred compensation (4) $ 2,182 $ - $ - $ 2,182 _____________ (1) Money market funds, certificates of deposit and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of September 30, 2017, and December 31, 2016, consisted of demand deposits . Commercial paper and certificates of deposit with an original maturity of over ninety days are included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets. See footnote (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets; other long-term assets; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date . (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in footnote (2) above .

Hedging Instruments (Tables)

Hedging Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative [Line Items]
Gain/(Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)	  Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion)  For the Three Months Ended For the Nine Months Ended  September 30, September 30,  Derivative instruments 2017 2016 2017 2016   Cash flow hedging derivatives:  Foreign currency exchange contracts, net of tax $ (2,530) $ (580) $ (9,059) $ (2,616)  Interest rate swaps, net of tax - - - 242  Total cash flow hedges $ (2,530) $ (580) $ (9,059) $ (2,374) 
Assets [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	  Hedging Assets  September 30, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Other current assets $ 855 $ 8,926  Foreign currency exchange contracts Other long-term assets 116 -  Total derivative instruments presented as cash flow hedges on the balance sheet 971 8,926  Gross amounts subject to master netting arrangements not offset on the balance sheet 971 679  Net amount $ - $ 8,247 
Liabilities [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	  Hedging Liabilities  September 30, December 31,  2017 2016   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Accrued liabilities $ 5,537 $ 1,081  Foreign currency exchange contracts Other long-term liabilities 1,467 -  Total derivative instruments presented as cash flow hedges on the balance sheet 7,004 1,081  Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 104,656 93,664  Total hedging instruments presented on the balance sheet 111,660 94,745  Gross amounts subject to master netting arrangements not offset on the balance sheet 971 679  Net amount $ 110,689 $ 94,066 

Accounting Policies (Summary Of

Accounting Policies (Summary Of The Most Significant Impacts Of The New Accounting Guidance) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Increase in operating activities		$ 252,150	$ 238,188
Decrease in financing activities		129,958	144,944
Accounting Standards Update 2016-09 [Member]
Effective Income Tax Rate Reconciliation, Deduction, Amount	$ 3,800	$ 22,100
Weighted Average Number Diluted Shares Outstanding Adjustment	450,000	450,000
Accounting Standards Update 2016-09 [Member] | Tax Benefits Related To Share-based Payments At Settlement Classified As Operating Cash Flows Instead Of Financing Cash Flows [Member]
Increase in operating activities		$ 22,100
Decrease in financing activities		22,100
Accounting Standards Update 2016-09 [Member] | Cash Payments To Tax Authorities For Shares Withheld To Meet Tax Withholding Requirements On Restricted Stock Units Are Classified As Financing Cash Flow Instead Of Operating Cash Flow [Member]
Increase in operating activities		7,800	3,700
Decrease in financing activities		$ 7,800	$ 3,700

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2017USD ($)entity	Jun. 30, 2017USD ($)entity	Mar. 31, 2017USD ($)	Sep. 30, 2017USD ($)
Business Acquisition [Line Items]
Acquisition of a business, net of cash acquired				$ 14,529
Reference Laboratory In United States [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 1,300
Number of businesses acquired | entity	3
Two Software Companies [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred		$ 15,000
Acquisition of a business, net of cash acquired		$ 12,000
Number of businesses acquired | entity		2
Business Combination, Contingent Consideration, Term For Payment Upon Completion Of Goals		36 months
Contingent payment		$ 3,000
Business Combinations, goodwill		13,300
Reference Laboratory In Austria [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred			$ 1,300
Customer Relationships [Member] | Two Software Companies [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,000
Technology-Based Intangible Assets [Member] | Two Software Companies [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 600

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-Based Compensation [Abstract]
Fair value of share-based compensation awards, granted	$ 1.5	$ 0.4	$ 31	$ 26.1
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	50.6		$ 50.6
Weighted average recognition period for unrecognized compensation expense, in years			1 year 10 months 24 days
Share-based compensation expense	$ 6.1		$ 17.8

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-Based Compensation [Abstract]
Share price at grant	$ 142.89	$ 68.94
Expected stock price volatility	26.00%	25.00%
Expected term, in years	5 years 9 months 18 days	5 years 8 months 12 days
Risk-free interest rate	2.00%	1.20%
Weighted average fair value of options granted	$ 40.83	$ 17.84

Marketable Securities (Amortize

Marketable Securities (Amortized Cost And Fair Value Of Marketable Securities) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 284,979	$ 236,995
Gross Unrealized Gains	163	70
Gross Unrealized Losses	(57)	(116)
Fair Value	285,085	236,949
Marketable securities that we consider to be other-than-temporarily impaired	0
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	139,533	130,833
Gross Unrealized Gains	129	40
Gross Unrealized Losses	(31)	(102)
Fair Value	139,631	130,771
Certificates Of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	60,473	40,400
Fair Value	60,473	40,400
Commercial Paper - Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,234	20,228
Fair Value	24,234	20,228
Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	22,476	27,290
Gross Unrealized Gains	11	25
Gross Unrealized Losses	(6)
Fair Value	22,481	27,315
U.S. Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	16,282	12,244
Gross Unrealized Gains	11	1
Gross Unrealized Losses	(7)	(14)
Fair Value	16,286	12,231
Treasury Bills [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	10,992
Gross Unrealized Gains	1
Fair Value	10,993
Agency Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	10,989	4,600
Gross Unrealized Gains	11	4
Gross Unrealized Losses	(13)
Fair Value	$ 10,987	4,604
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,400
Fair Value		$ 1,400

Marketable Securities (Contract

Marketable Securities (Contractual Maturities Of Marketable Securities) (Details) $ in Thousands	Sep. 30, 2017USD ($)
Marketable Securities [Abstract]
Due in one year or less, Amortized Cost	$ 180,221
Due after one year through three years, Amortized Cost	104,758
Total marketable securities, Amortized Cost	284,979
Due in one year or less, Fair Value	180,236
Due after one year through three years, Fair Value	104,849
Total marketable securities, Fair Value	$ 285,085

Inventories (Schedule Of Compon

Inventories (Schedule Of Components Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventories [Abstract]
Raw materials	$ 32,254	$ 27,561
Work-in-process	18,200	14,998
Finished goods	126,295	115,475
Inventories	$ 176,749	$ 158,034

Goodwil And Intangible Assets,

Goodwil And Intangible Assets, Net (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)
Goodwill and Intangible Assets, Net [Abstract]
Impairment charge	$ 2.2

Other Current and Long-Term A51

Other Current and Long-Term Assets (Schedule Of Other Current Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Current and Long-Term Assets [Abstract]
Prepaid expenses	$ 28,233	$ 25,746
Taxes receivable	20,438	27,672
Customer acquisition costs, net	22,158	18,085
Other assets	12,881	19,703
Other current assets	$ 83,710	$ 91,206

Other Current and Long-Term A52

Other Current and Long-Term Assets (Schedule Of Other Long-term Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Current and Long-Term Assets [Abstract]
Investment in long-term product supply arrangements	$ 9,060	$ 10,978
Customer acquisition costs, net	62,242	50,309
Other assets	35,111	36,321
Deferred income taxes	7,914	5,707
Other long-term assets	$ 114,327	$ 103,315

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Accrued expenses	$ 60,774	$ 71,984
Accrued employee compensation and related expenses	79,687	91,113
Accrued taxes	24,859	23,973
Accrued customer programs	55,187	49,061
Accrued liabilities	$ 220,507	$ 236,131

Repurchases Of Common Stock (De

Repurchases Of Common Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Repurchases Of Common Stock [Abstract]
Shares repurchased in the open market	312	142	1,398	1,119
Shares acquired through employee surrender for statutory tax withholding	2	2	55	56
Total shares repurchased	314	144	1,453	1,175
Cost of shares repurchased in the open market	$ 50,413	$ 15,260	$ 215,320	$ 88,235
Cost of shares for employee surrenders	370	218	7,829	3,950
Total cost of shares	$ 50,783	$ 15,478	$ 223,149	$ 92,185
Average cost per share - open market repurchase	$ 161.57	$ 107.38	$ 153.99	$ 78.84
Average cost per share - employee surrenders	155.14	112.91	142.15	70.33
Average cost per share - total	$ 161.52	$ 107.46	$ 153.54	$ 78.43

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Taxes [Abstract]
Effective Tax Rate	23.40%	30.80%	22.80%	30.70%
Effective Income Tax Rate Reconciliation, Deduction, Dividend, Percent	4.00%		8.00%
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent	3.00%

Accumulated Other Comprehensi56

Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Balance, value	$ (108,213)
Balance, value	(48,391)
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Balance, value	(43,053)
Other comprehensive income (loss) before reclassifications	8,992
Gains reclassified from accumulated other comprehensive income	(587)
Balance, value	(34,648)
Unrealized Gain on Investments, Net of Tax [Member]
Balance, value	20
Other comprehensive income (loss) before reclassifications	109
Balance, value	129
Unrealized Gain (Loss) on Derivative Instruments, Net of Tax [Member]
Balance, value	4,916
Other comprehensive income (loss) before reclassifications	(8,472)
Gains reclassified from accumulated other comprehensive income	(587)
Balance, value	(4,143)
Unrealized Gain (Loss) on Net Investment Hedge, Net of Tax [Member]
Balance, value	4,036
Other comprehensive income (loss) before reclassifications	(6,895)
Balance, value	(2,859)
Cumulative Translation Adjustment [Member]
Balance, value	(52,025)
Other comprehensive income (loss) before reclassifications	24,250
Balance, value	$ (27,775)

Accumulated Other Comprehensi57

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Tax expense (benefits)	$ 21,535	$ 25,072	$ 66,392	$ 75,036
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(893)	648	935	1,117
Tax expense (benefits)	(333)	197	348	313
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(560)	451	587	804
Foreign Currency Exchange Contracts [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$ (893)	$ 648	$ 935	1,538
Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax				$ (421)

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Shares outstanding for basic earnings per share	87,537	89,894	87,884	89,881
Dilutive effect of share-based payment awards	1,719	1,244	1,851	1,079
Shares outstanding for diluted earnings per share	89,256	91,138	89,735	90,960

Earnings Per Share (Schedule 59

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock Options [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options	377		310	520
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options

Segment Reporting (Summary Of S

Segment Reporting (Summary Of Segment Performance) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 491,976	$ 448,308	$ 1,462,937	$ 1,332,427
Income (loss) from operations	100,413	88,459	315,220	266,414
Interest expense, net	(8,364)	(6,935)	(23,849)	(21,695)
Income before provision for income taxes	92,049	81,524	291,371	244,719
Provision for income taxes	21,535	25,072	66,392	75,036
Net income	70,514	56,452	224,979	169,683
Less: Net income attributable to noncontrolling interest	3	(3)	92	7
Net income attributable to IDEXX Laboratories, Inc. stockholders	70,511	56,455	224,887	169,676
Depreciation and amortization			61,620	57,977
Expenditures for long-lived assets			54,370	49,956
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	426,686	385,288	1,269,861	1,143,150
Income (loss) from operations	89,271	77,493	277,857	229,858
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	31,030	27,862	85,531	79,243
Income (loss) from operations	14,505	12,442	38,421	34,864
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	28,396	29,799	91,266	93,511
Income (loss) from operations	902	3,026	9,880	12,665
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	5,864	5,359	16,279	16,523
Income (loss) from operations	2,114	1,008	3,275	(749)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Income (loss) from operations	$ (6,379)	$ (5,510)	$ (14,213)	$ (10,224)

Segment Reporting (Summary Of R

Segment Reporting (Summary Of Revenue By Product And Service Category) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 491,976	$ 448,308	$ 1,462,937	$ 1,332,427
Revenue, Reclassified Between Segments	400		1,100
CAG Diagnostics Recurring Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	364,937	324,603	1,091,936	969,097
IDEXX Vetlab Consumables [Member]
Segment Reporting Information [Line Items]
Revenue	129,434	113,964	385,081	336,493
Rapid Assay Products [Member]
Segment Reporting Information [Line Items]
Revenue	50,924	48,720	159,085	147,583
Reference Laboratory Diagnostic And Consulting Services [Member]
Segment Reporting Information [Line Items]
Revenue	167,851	146,672	498,218	440,514
CAG Diagnostics Service And Accessories [Member]
Segment Reporting Information [Line Items]
Revenue	16,728	15,247	49,552	44,507
CAG Diagnostic Capital - Instruments [Member]
Segment Reporting Information [Line Items]
Revenue	29,119	31,255	83,018	86,063
Veterinary Software, Services and Diagnostic Imaging Systems [Member]
Segment Reporting Information [Line Items]
Revenue	32,630	29,430	94,907	87,990
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	426,686	385,288	1,269,861	1,143,150
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	31,030	27,862	85,531	79,243
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	28,396	29,799	91,266	93,511
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,864	$ 5,359	$ 16,279	$ 16,523

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Carrying value of long-term debt	$ 604,149	$ 593,110
Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt, Fair Value	$ 631,000	$ 609,500

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 285,085	$ 236,949
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	139,631	130,771
Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	60,473	40,400
Commercial Paper - Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	24,234	20,228
Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	22,481	27,315
U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	16,286	12,231
Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,993
Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		1,400
Measured At Fair Value On Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	285,085	236,949
Measured At Fair Value On Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	285,085	236,949
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,119	2,182
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,119	2,182
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	971	8,926
Fair value of Liabilities	7,004	1,081
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	971	8,926
Fair value of Liabilities	7,004	1,081
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,119	2,182
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,119	2,182
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	20,924	34,208
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	20,924	34,208
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit - Maturity Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets		1,500
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit - Maturity Less Than 90 Days [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets		1,500
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	3,089	898
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	3,089	898
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,500
Total marketable securities	139,631	130,771
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,500
Total marketable securities	139,631	130,771
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	750
Total marketable securities	60,473	40,400
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	750
Total marketable securities	60,473	40,400
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper - Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	24,234	20,228
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper - Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	24,234	20,228
Measured At Fair Value On Recurring Basis [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	22,481	27,315
Measured At Fair Value On Recurring Basis [Member] | Asset-backed Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	22,481	27,315
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	16,286	12,231
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	16,286	12,231
Measured At Fair Value On Recurring Basis [Member] | Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,993
Measured At Fair Value On Recurring Basis [Member] | Treasury Bills [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,993
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds- Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,987	4,604
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds- Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 10,987	4,604
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		1,400
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		$ 1,400

Hedging Instruments (Narrative)

Hedging Instruments (Narrative) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017EUR (€)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Derivative [Line Items]
Estimated net amount of gains expected to be reclassified out of accumulated other comprehensive income and into earnings within next 12 months			$ 3,200
Cash Flow Hedge, hedge percentage of estimated exposure from intercompany products purchases and sales			85.00%
General duration of foreign currency exchange contracts			24 months
Notional Amount of Foreign Currency Exchange Contracts						$ 184,500	$ 175,900
Unrealized loss on net investment hedge	$ (2,035)	$ (732)	$ (6,895)	$ (1,649)
Series C Senior Note [Member]
Derivative [Line Items]
Debt instrument, face amount | €					€ 88,900,000
Stated interest rate					1.785%	1.785%
Interest Rate Swap Effective On March 30, 2012 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap					1.36%	1.36%
Credit Facility borrowings hedged						$ 40,000
Interest Rate Swap Effective On March 28, 2013 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap					1.64%	1.64%
Credit Facility borrowings hedged						$ 40,000

Hedging Instruments (Schedule O

Hedging Instruments (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 111,660	$ 94,745
Hedging Liabilities, Gross amounts subject to master netting arrangements not offset on the balance sheet	971	679
Hedging Liabilities, Net amount	110,689	94,066
Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	7,004	1,081
Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Gross amounts subject to master netting arrangements not offset on the balance sheet	971	679
Hedging Assets, Net amount		8,247
Derivatives Designated As Hedging Instruments [Member] | Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	971	8,926
Foreign Currency Exchange Contracts [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	5,537	1,081
Foreign Currency Exchange Contracts [Member] | Other Long-Term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	1,467
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	855	8,926
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Long-Term Assets, Net [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	116
Foreign Currency Borrowings Designated As Net Investment Hedge On The Balance Sheet [Member] | Long-term Debt [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 104,656	$ 93,664

Hedging Instruments ((Loss) Gai

Hedging Instruments ((Loss) Gain Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)) (Details) - Derivatives Designated As Hedging Instruments [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	$ (2,530)	$ (580)	$ (9,059)	$ (2,374)
Foreign Currency Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	$ (2,530)	$ (580)	$ (9,059)	(2,616)
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax				$ 242